secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aspira Women's Health Inc. (AWHL)
CIK:        0000926617
Form:       8-K
Filed at:   2022-11-10T23:59:59+00:00
Accession:  0000926617-22-000054
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aspira Women's Health Q3 product revenue up 26% to $2.0M; CFO departing Dec 1
-----------------------------------------------------------------------------

- Q3 product revenue $2.037M (+26% YoY); Ova1Plus volume 5,524 (+29% YoY); gross margin 57%.
- CFO Robert Beechey to depart Dec 1; will serve as consultant during successor search.
- OvaWatch launch planned Q4 2022; ovarian cancer portfolio rebranded as OvaSuite.
- Sponsored research agreement with Harvard Dana Farber, Brigham & Women's, and Medical Univ. of Lodz for endometriosis test.
- Co-marketing with BioReference launched in Q4; raised $9M gross ($7.7M net) in public offering.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/926617/000092661722000054/0000926617-22-000054-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/926617/000092661722000054/awh-20221110x8k.htm
  HTML page:      https://secwatch.observer/filing/0000926617-22-000054

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer